|
Tuesday, September 22, 2020 |
|
아방스 클리니컬, 바이오팜 아메리카에서 생명공학 임상시험을 위한 전자임상시험 솔루션 확대 발표 |
호주의 앞서가는 생명공학 임상시험수탁기관(CRO)이자 프로스트&설리번(Frost & Sullivan)이 수여하는 2020년 아시아태평양 CRO 마켓 리더십 어워드(2020 Asia-Pacific CRO Market Leadership Award)를 수상한 아방스 클리니컬(Avance Clinical)은 개선된 환자 참여, 가시성, 데이터 수집, 분석 등 선진 디지털 임상 수단을 통해 전자임상시험 솔루션(eClinical Solution) 서비스를 확장하고 있다. www.avancecro.com/eclinical-solutions more info >> |
|
Avance Clinical宣布为美国BioPharm的生物技术临床试验研究 扩大电子临床解决方案 |
澳大利亚领先的生物技术CRO以及Frost&Sullivan 2020年亚太CRO市场领导奖的获得者,Avance Clinical扩展了其电子临床解决方案产品,提供了先进的数字临床工具以增强患者参与度,可视性,数据收集和分析。 www.avancecro.com/eclinical-solutions more info >> |
|
Avance Clinical宣佈為美國BioPharm的生物技術臨床試驗研究 擴大電子臨床解決方案 |
澳大利亞領先的生物技術CRO以及Frost&Sullivan 2020年亞太CRO市場領導獎的獲得者,Avance Clinical擴展了其電子臨床解決方案產品,提供了先進的數字臨床工具以增強患者參與度,可視性,數據收集和分析。 www.avancecro.com/eclinical-solutions more info >> |
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
Friday, September 4, 2020 |
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
Thursday, July 23, 2020 |
|
Avance Clinical签约展开Atossa Therapeutics AT-301鼻喷雾剂临床研究,这是Atossa的第二个新冠肺炎治疗开发项目 |
澳大利亚领先的生物技术CRO和Frost & Sullivan 2020年亚太区CRO市场领导奖获得者Avance Clinical正式签约,对Atossa Therapeutics的专利候选药物AT-301进行临床研究,该药物将通过鼻喷雾剂给药。Avance已经成功地完成了Atossa专利Endoxifen的多项临床研究。 more info >> |
|
Avance Clinical簽約展開Atossa Therapeutics AT-301鼻噴霧劑臨床研究,這是Atossa的第二個新冠肺炎治療開發項目 |
澳大利亞領先的生物技術CRO和Frost & Sullivan 2020年亞太區CRO市場領導獎獲得者Avance Clinical正式簽約,對Atossa Therapeutics的專利候選藥物AT-301進行臨床研究,該藥物將通過鼻噴霧劑給藥。 Avance已經成功地完成了Atossa專利Endoxifen的多項臨床研究。 more info >> |
|
아방스 클리니컬, 아토사 테라퓨틱스의 두 번째 코로나19 치료제 개발 프로그램인 비강 분무용 치료제 AT-301 임상 연구 계약 |
호주의 앞서가는 바이오텍 임상시험수탁기관(CRO)이자 프로스트 앤 설리번(Frost & Sullivan)이 ‘2020 아시아 태평양 CRO 시장 선두기관’으로 선정한 아방스 클리니컬(Avance Clinical)은 아토사 테라퓨틱스(Atossa Therapeutics)의 비강 분무용 전매 신약 후보인 AT-301 관련 임상 연구 시행 계약을 맺었다. 아방스 클리니컬은 아토사 테라퓨틱스의 전매 약제인 엔독시펜(Endoxifen) 임상 연구를 몇 차례 성공적으로 완료한 바 있다. more info >> |
|
Wednesday, July 22, 2020 |
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
Thursday, July 9, 2020 |
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
|
|